

NanoEntek Launches EVE-HT A26, a Fully Automated High-Throughput Cell Counter for the Global CDMO Market


Delivers a 100% automated workflow from sample preparation to analysis, resolving bottlenecks in large-scale bioprocessing

CA, UNITED STATES, July 14, 2026

/EINPresswire.com/ -- □ Delivers a 100% automated workflow from sample preparation to analysis, resolving bottlenecks in large-scale bioprocessing

□ Building on supply references with leading global biopharma companies to expand market reach amid growing demand in the CGT sector

NanoEntek has launched EVE-HT A26, a fully automated high-throughput cell counter, marking the company's strategic expansion into the global bioprocessing and [CDMO](#) (Contract Development and Manufacturing Organization) market.



NanoEntek has launched EVE-HT A26

Built on the advanced core technology of NanoEntek's EVE-HT series, EVE-HT A26 is a next-generation platform that automates the entire workflow — from cell preparation and staining to counting and analysis. The system features a 7-axis robotic architecture that integrates NanoEntek's proprietary Bio-MEMS technology with linear motor drives and precision robotic pipetting, delivering exceptional throughput, accuracy, and ease of use in a single instrument.

EVE-HT A26 stands out for its ultra-fast processing speed and exceptional sample efficiency. The system processes up to 96 samples in just 10 minutes — fully unattended, from staining through analysis — compared with the more than three hours typically required by competing systems. Unlike competing instruments that require 170 μ L or more per test, EVE-HT A26 delivers high-

precision analysis with as little as 20 μ L, translating into significant cost savings and improved yield for research and production environments working with high-value cell types.

"EVE-HT A26 represents the next generation of cell counting technology, combining exceptional speed, precision, and fully integrated automation in a single platform," said a NanoEntek official. "We expect EVE-HT A26 to maximize operational efficiency and bring a paradigm shift to cell counting workflows at CDMOs and biopharmaceutical research and manufacturing facilities worldwide."

Amy Kim
Nano Entek
amy@nanoentek.com



This press release can be viewed online at: <https://www.einpresswire.com/article/926284883>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.